Maria Roche

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

Michael C. Heinrich, Robin L. Jones, Margaret von Mehren et al. · The Lancet Oncology · 2020 · 304 citations

Medicine, Oncology, Pharmacotherapy +9

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

Ursula A. Matulonis, Suzanne Berlin, Percy Ivy et al. · Journal of Clinical Oncology · 2009 · 301 citations · Full text

Medicine, Oncology, Pharmacology +11

Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism

Alexandra Zanin‐Zhorov, Jonathan M. Weiss, Melanie Nyuydzefe et al. · Proceedings of the National Academy of Sciences · 2014 · 253 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: <i>In Vitro</i> and <i>In Vivo</i> Preclinical Models

Elayne Chan-Penebre, Kelli Armstrong, Allison E. Drew et al. · Molecular Cancer Therapeutics · 2017 · 168 citations

Medicine, Molecular Biology, Oncology +17

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial

Robin L. Jones, César Serrano, Margaret von Mehren et al. · European Journal of Cancer · 2021 · 136 citations · Full text

Medicine, Oncology, Pharmacology +17